About this Journal Submit a Manuscript Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 970586, 14 pages
http://dx.doi.org/10.1155/2013/970586
Review Article

Advanced MR Imaging of Gliomas: An Update

1Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming University, No. 155, Sec. 2, Linong Street, Taipei 112, Taiwan
2Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, No. 325, Sec. 2, Cheng-Kong Road, Neihu, Taipei 114, Taiwan
3Department of Electrical Engineering, National Taiwan University, No. 1, Sec. 4, Roosevelt Road, Taipei 106, Taiwan
4Imaging Research Center, Taipei Medical University, No. 250, Wu-Hsing Street, Taipei 110, Taiwan
5Department of Radiological Sciences, University of California at Irvine Medical Center, Irvine, 101 The City Drive South, Orange, CA 92868, USA

Received 9 January 2013; Revised 12 April 2013; Accepted 13 May 2013

Academic Editor: Shaoli Song

Copyright © 2013 Hung-Wen Kao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. N. Louis, “Molecular pathology of malignant gliomas,” Annual Review of Pathology, vol. 1, pp. 97–117, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Y. Wen and S. Kesari, “Malignant gliomas in adults,” New England Journal of Medicine, vol. 359, no. 5, pp. 492–507, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Kleihues and H. Ohgaki, “Primary and secondary glioblastomas: from concept to clinical diagnosis,” Neuro-Oncology, vol. 1, no. 1, pp. 44–51, 1999. View at Scopus
  4. W. A. Freije, F. E. Castro-Vargas, Z. Fang et al., “Gene expression profiling of gliomas strongly predicts survival,” Cancer Research, vol. 64, no. 18, pp. 6503–6510, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Reifenberger and V. P. Collins, “Pathology and molecular genetics of astrocytic gliomas,” Journal of Molecular Medicine, vol. 82, no. 10, pp. 656–670, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Yamanaka, T. Arao, N. Yajima et al., “Identification of expressed genes characterizing long-term survival in malignant glioma patients,” Oncogene, vol. 25, no. 44, pp. 5994–6002, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. M. E. Figueroa, O. Abdel-Wahab, C. Lu et al., “Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation,” Cancer Cell, vol. 18, no. 6, pp. 553–567, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Thon, S. Eigenbrod, S. Kreth et al., “IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival,” Cancer, vol. 118, no. 2, pp. 452–460, 2012.
  9. C. Walker, D. G. Du Plessis, K. A. Joyce et al., “Molecular pathology and clinical characteristics of oligodendroglial neoplasms,” Annals of Neurology, vol. 57, no. 6, pp. 855–865, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. J. S. Smith, A. Perry, T. J. Borell et al., “Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas,” Journal of Clinical Oncology, vol. 18, no. 3, pp. 636–645, 2000. View at Scopus
  11. H. Ohgaki, P. Dessen, B. Jourde et al., “Genetic pathways to glioblastoma: a population-based study,” Cancer Research, vol. 64, no. 19, pp. 6892–6899, 2004. View at Publisher · View at Google Scholar · View at Scopus
  12. B. K. A. Rasheed, R. E. McLendon, H. S. Friedman et al., “Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25,” Oncogene, vol. 10, no. 11, pp. 2243–2246, 1995. View at Scopus
  13. M. Nakamura, F. Yang, H. Fujisawa, Y. Yonekawa, P. Kleihues, and H. Ohgaki, “Loss of heterozygosity on chromosome 19 in secondary glioblastomas,” Journal of Neuropathology and Experimental Neurology, vol. 59, no. 6, pp. 539–543, 2000. View at Scopus
  14. T. Homma, T. Fukushima, S. Vaccarella et al., “Correlation among pathology, genotype, and patient outcomes in glioblastoma,” Journal of Neuropathology and Experimental Neurology, vol. 65, no. 9, pp. 846–854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. W. J. Curran Jr., C. B. Scott, J. Horton et al., “Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials,” Journal of the National Cancer Institute, vol. 85, no. 9, pp. 704–710, 1993. View at Scopus
  16. M. D. Prados, W. Seiferheld, H. M. Sandler et al., “Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404,” International Journal of Radiation Oncology Biology Physics, vol. 58, no. 4, pp. 1147–1152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Cao, P. C. Sundgren, C. I. Tsien, T. T. Chenevert, and L. Junck, “Physiologic and metabolic magnetic resonance imaging in gliomas,” Journal of Clinical Oncology, vol. 24, no. 8, pp. 1228–1235, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. M. D. Jenkinson, D. G. D. Plessis, C. Walker, and T. S. Smith, “Advanced MRI in the management of adult gliomas,” British Journal of Neurosurgery, vol. 21, no. 6, pp. 550–561, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. J. Price, “The role of advanced MR imaging in understanding brain tumour pathology,” British Journal of Neurosurgery, vol. 21, no. 6, pp. 562–575, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Gupta, R. J. Young, S. Karimi et al., “Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma,” American Journal of Neuroradiology, vol. 32, no. 7, pp. 1301–1306, 2011.
  21. L. S. Hu, J. M. Eschbacher, A. C. Dueck et al., “Correlations between perfusion MR imaging cerebral blood volume, microvessel quantification, and clinical outcome using stereotactic analysis in recurrent high-grade glioma,” American Journal of Neuroradiology, vol. 33, no. 1, pp. 69–76, 2012.
  22. K. Noguchi, N. Watanabe, T. Nagayoshi et al., “Role of diffusion-weighted echo-planar MRI in distinguishing between brain abscess and tumour: a preliminary report,” Neuroradiology, vol. 41, no. 3, pp. 171–174, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. T. W. Stadnik, C. Chaskis, A. Michotte et al., “Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histologic findings,” American Journal of Neuroradiology, vol. 22, no. 5, pp. 969–976, 2001. View at Scopus
  24. S. Higano, X. Yun, T. Kumabe et al., “Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis,” Radiology, vol. 241, no. 3, pp. 839–846, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Sugahara, Y. Korogi, M. Kochi et al., “Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas,” Journal of Magnetic Resonance Imaging, vol. 9, no. 1, pp. 53–60, 1999.
  26. Y. Kang, S. H. Choi, Y. J. Kim et al., “Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging—correlation with tumor grade,” Radiology, vol. 261, no. 3, pp. 882–890, 2011.
  27. S. Mori, K. Frederiksen, P. C. M. Van Zijl et al., “Brain white matter anatomy of tumor patients evaluated with diffusion tensor imaging,” Annals of Neurology, vol. 51, no. 3, pp. 377–380, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. S. J. Price, N. G. Burnet, T. Donovan et al., “Diffusion tensor imaging of brain tumours at 3 T: a potential tool for assessing white matter tract invasion?” Clinical Radiology, vol. 58, no. 6, pp. 455–462, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Lu, D. Ahn, G. Johnson, and S. Cha, “Peritumoral diffusion tensor imaging of high-grade gliomas and metastatic brain tumors,” American Journal of Neuroradiology, vol. 24, no. 5, pp. 937–941, 2003. View at Scopus
  30. T. Inoue, K. Ogasawara, T. Beppu, A. Ogawa, and H. Kabasawa, “Diffusion tensor imaging for preoperative evaluation of tumor grade in gliomas,” Clinical Neurology and Neurosurgery, vol. 107, no. 3, pp. 174–180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Goebell, S. Paustenbach, O. Vaeterlein et al., “Low-grade and anaplastic gliomas: differences in architecture evaluated with diffusion-tensor MR imaging,” Radiology, vol. 239, no. 1, pp. 217–222, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. A. I. Holodny, M. D. Ollenschleger, W. C. Liu, M. Schulder, and A. J. Kalnin, “Identification of the corticospinal tracts achieved using blood-oxygen-level-dependent and diffusion functional MR imaging in patients with brain tumors,” American Journal of Neuroradiology, vol. 22, no. 1, pp. 83–88, 2001. View at Scopus
  33. M. Schulder, J. A. Maldjian, W. C. Liu et al., “Functional image-guided surgery of intracranial tumors located in or near the sensorimotor cortex,” Journal of Neurosurgery, vol. 89, no. 3, pp. 412–418, 1998. View at Scopus
  34. J. H. Jensen, J. A. Helpern, A. Ramani, H. Lu, and K. Kaczynski, “Diffusional kurtosis imaging: the quantification of non-Gaussian water diffusion by means of magnetic resonance imaging,” Magnetic Resonance in Medicine, vol. 53, no. 6, pp. 1432–1440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Van Cauter, J. Veraart, J. Sijbers et al., “Gliomas: diffusion kurtosis MR imaging in grading,” Radiology, vol. 263, no. 2, pp. 492–501, 2012.
  36. H. Wakimoto, M. Aoyagi, T. Nakayama et al., “Prognostic significance of Ki-67 labeling indices obtained using MIB-1 monoclonal antibody in patients with supratentorial astrocytomas,” Cancer, vol. 77, no. 2, pp. 373–380, 1996.
  37. T. Hoshino, D. Ahn, M. D. Prados, K. Lamborn, and C. B. Wilson, “Prognostic significance of the proliferative potential of intracranial gliomas measured by bromodeoxyuridine labeling,” International Journal of Cancer, vol. 53, no. 4, pp. 550–555, 1993. View at Scopus
  38. P. E. Mckeever, D. A. Ross, M. S. Strawderman, J. A. Brunberg, H. S. Greenberg, and L. Junck, “A comparison of the predictive power for survival in gliomas provided by MIB-1, bromodeoxyuridine and proliferating cell nuclear antigen with histopathologic and clinical parameters,” Journal of Neuropathology and Experimental Neurology, vol. 56, no. 7, pp. 798–805, 1997. View at Scopus
  39. P. K. Sallinen, H. K. Haapasalo, T. Visakorpi et al., “Prognostication of astrocytoma patient survival by Ki-67 (MIB-1), PCNA, and S-phase fraction using archival paraffin-embedded samples,” Journal of Pathology, vol. 174, no. 4, pp. 275–282, 1994. View at Scopus
  40. O. Tynninen, H. J. Aronen, M. Ruhala et al., “MRI enhancement and microvascular density in gliomas. Correlation with tumor cell proliferation,” Investigative Radiology, vol. 34, no. 6, pp. 427–434, 1999. View at Publisher · View at Google Scholar · View at Scopus
  41. R. Kiss, O. Dewitte, C. Decaestecker et al., “The combined determination of proliferative activity and cell density in the prognosis of adult patients with supratentorial high-grade astrocytic tumors,” American Journal of Clinical Pathology, vol. 107, no. 3, pp. 321–331, 1997. View at Scopus
  42. N. Sadeghi, I. Salmon, C. Decaestecker et al., “Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma,” American Journal of Neuroradiology, vol. 28, no. 3, pp. 455–461, 2007. View at Scopus
  43. G. Barbarella, R. Ricci, G. Pirini et al., “In vivo single voxel 1H MRS of glial brain tumors: correlation with tissue histology and in vitro MRS,” International Journal of Oncology, vol. 12, no. 2, pp. 461–468, 1998. View at Scopus
  44. H. Shimizu, T. Kumabe, R. Shirane, and T. Yoshimoto, “Correlation between choline level measured by proton MR spectroscopy and Ki-67 labeling index in gliomas,” American Journal of Neuroradiology, vol. 21, no. 4, pp. 659–665, 2000. View at Scopus
  45. A. Matsumura, T. Isobe, I. Anno, S. Takano, and H. Kawamura, “Correlation between choline and MIB-1 index in human gliomas. A quantitative in proton MR spectroscopy study,” Journal of Clinical Neuroscience, vol. 12, no. 4, pp. 416–420, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. T. Tamiya, K. Kinoshita, Y. Ono, K. Matsumoto, T. Furuta, and T. Ohmoto, “Proton magnetic resonance spectroscopy reflects cellular proliferative activity in astrocytomas,” Neuroradiology, vol. 42, no. 5, pp. 333–338, 2000. View at Scopus
  47. T. R. Mcknight, K. R. Lamborn, T. D. Love et al., “Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas,” Journal of Neurosurgery, vol. 106, no. 4, pp. 660–666, 2007. View at Publisher · View at Google Scholar · View at Scopus
  48. R. Guillevin, C. Menuel, H. Duffau et al., “Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas,” Journal of Neuro-Oncology, vol. 87, no. 2, pp. 181–187, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Castillo, J. K. Smith, and L. Kwock, “Correlation of myo-inositol levels and grading of cerebral astrocytomas,” American Journal of Neuroradiology, vol. 21, no. 9, pp. 1645–1649, 2000. View at Scopus
  50. K. H. Plate, G. Breier, H. A. Weich, and W. Risau, “Vascular endothelial growth factor is a potential tumour angiogenssis factor in human gliomas in vivo,” Nature, vol. 359, no. 6398, pp. 845–848, 1992. View at Publisher · View at Google Scholar · View at Scopus
  51. O. Kargiotis, J. S. Rao, and A. P. Kyritsis, “Mechanisms of angiogenesis in gliomas,” Journal of Neuro-Oncology, vol. 78, no. 3, pp. 281–293, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. M. R. Machein and K. H. Plate, “VEGF in brain tumors,” Journal of Neuro-Oncology, vol. 50, no. 1-2, pp. 109–120, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. D. R. Senger, L. Van De Water, L. F. Brown et al., “Vascular permeability factor (VPF, VEGF) in tumor biology,” Cancer and Metastasis Reviews, vol. 12, no. 3-4, pp. 303–324, 1993. View at Scopus
  54. H. Ashrafpour, N. Huang, P. C. Neligan et al., “Vasodilator effect and mechanism of action of vascular endothelial growth factor in skin vasculature,” American Journal of Physiology, vol. 286, no. 3, pp. H946–H954, 2004. View at Scopus
  55. D. D. Ku, J. K. Zaleski, S. Liu, and T. A. Brock, “Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries,” American Journal of Physiology, vol. 265, no. 2, part 2, pp. H586–H592, 1993. View at Scopus
  56. D. R. Senger, S. J. Galli, A. M. Dvorak, C. A. Perruzzi, V. Susan Harvey, and H. F. Dvorak, “Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid,” Science, vol. 219, no. 4587, pp. 983–985, 1983. View at Scopus
  57. P. Vajkoczy and M. D. Menger, “Vascular microenvironment in gliomas,” Cancer Treatment and Research, vol. 117, pp. 249–262, 2004. View at Scopus
  58. N. A. Vick and D. D. Bigner, “Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function,” Journal of the Neurological Sciences, vol. 17, no. 1, pp. 29–39, 1972. View at Scopus
  59. P. Birner, M. Piribauer, I. Fischer et al., “Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes,” Brain Pathology, vol. 13, no. 2, pp. 133–143, 2003. View at Scopus
  60. L. Østergaard, “Principles of cerebral perfusion imaging by bolus tracking,” Journal of Magnetic Resonance Imaging, vol. 22, no. 6, pp. 710–717, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. H. J. Aronen, F. S. Pardo, D. N. Kennedy et al., “High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas,” Clinical Cancer Research, vol. 6, no. 6, pp. 2189–2200, 2000. View at Scopus
  62. B. L. Dean, C. Lee, J. E. Kirsch, V. M. Runge, R. M. Dempsey, and L. C. Pettigrew, “Cerebral hemodynamics and cerebral blood volume: MR assessment using gadolinium contrast agents and T1-weighted turbo-FLASH imaging,” American Journal of Neuroradiology, vol. 13, no. 1, pp. 39–48, 1992. View at Scopus
  63. T. Hackländer, J. R. Reichenbach, M. Hofer, and U. Mödder, “Measurement of cerebral blood volume via the relaxing effect of low-dose gadopentetate dimeglumine during bolus transit,” American Journal of Neuroradiology, vol. 17, no. 5, pp. 821–830, 1996. View at Scopus
  64. J. L. Boxerman, K. M. Schmainda, and R. M. Weisskoff, “Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not,” American Journal of Neuroradiology, vol. 27, no. 4, pp. 859–867, 2006. View at Scopus
  65. R. Stupp, W. P. Mason, M. J. Van Den Bent et al., “Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,” New England Journal of Medicine, vol. 352, no. 10, pp. 987–996, 2005. View at Publisher · View at Google Scholar · View at Scopus
  66. D. Brandsma, L. Stalpers, W. Taal, P. Sminia, and M. J. van den Bent, “Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas,” The Lancet Oncology, vol. 9, no. 5, pp. 453–461, 2008. View at Publisher · View at Google Scholar · View at Scopus
  67. A. A. Brandes, E. Franceschi, A. Tosoni et al., “MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2192–2197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  68. R. Mangla, G. Singh, D. Ziegelitz et al., “Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy can help predict overall survival in patients with glioblastoma,” Radiology, vol. 256, no. 2, pp. 575–584, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. T. Sugahara, Y. Korogi, S. Tomiguchi et al., “Posttherapeutic intraaxial brain tumor: the value of perfusion-sensitive contrast-enhanced MR imaging for differentiating tumor recurrence from nonneoplastic contrast-enhancing tissue,” American Journal of Neuroradiology, vol. 21, no. 5, pp. 901–909, 2000. View at Scopus
  70. X. P. Zhu, K. L. Li, I. D. Kamaly-Asl et al., “Quantification of endothelial permeability, leakage space, and blood volume in brain tumors using combined T1 and T2* contrast-enhanced dynamic MR imaging,” Journal of Magnetic Resonance Imaging, vol. 11, no. 6, pp. 575–585, 2000.
  71. K. L. Li, X. P. Zhu, D. R. Checkley et al., “Simultaneous mapping of blood volume and endothelial permeability surface area product in gliomas using iterative analysis of first-pass dynamic contrast enhanced MRI data,” British Journal of Radiology, vol. 76, no. 901, pp. 39–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  72. H. C. Roberts, T. P. L. Roberts, R. C. Brasch, and W. P. Dillon, “Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade,” American Journal of Neuroradiology, vol. 21, no. 5, pp. 891–899, 2000. View at Scopus
  73. J. M. Provenzale, G. R. Wang, T. Brenner, J. R. Petrella, and A. G. Sorensen, “Comparison of permeability in high-grade and low-grade brain tumors using dynamic susceptibility contrast MR imaging,” American Journal of Roentgenology, vol. 178, no. 3, pp. 711–716, 2002. View at Scopus
  74. S. J. Mills, T. A. Patankar, H. A. Haroon, D. Balériaux, R. Swindell, and A. Jackson, “Do cerebral blood volume and contrast transfer coefficient predict prognosis in human glioma?” American Journal of Neuroradiology, vol. 27, no. 4, pp. 853–858, 2006. View at Scopus
  75. B. Ding, H. W. Ling, K. M. Chen, H. Jiang, and Y. B. Zhu, “Comparison of cerebral blood volume and permeability in preoperative grading of intracranial glioma using CT perfusion imaging,” Neuroradiology, vol. 48, no. 10, pp. 773–781, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. S. K. Ellika, R. Jain, S. C. Patel et al., “Role of perfusion CT in glioma grading and comparison with conventional MR imaging features,” American Journal of Neuroradiology, vol. 28, no. 10, pp. 1981–1987, 2007. View at Publisher · View at Google Scholar · View at Scopus
  77. P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
  78. F. Kazazi-Hyseni, J. H. Beijnen, and J. H. M. Schellens, “Bevacizumab,” Oncologist, vol. 15, no. 8, pp. 819–825, 2010. View at Publisher · View at Google Scholar · View at Scopus
  79. N. Ferrara, K. J. Hillan, H. P. Gerber, and W. Novotny, “Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer,” Nature Reviews Drug Discovery, vol. 3, no. 5, pp. 391–400, 2004. View at Scopus
  80. L. G. Presta, H. Chen, S. J. O'Connor et al., “Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders,” Cancer Research, vol. 57, no. 20, pp. 4593–4599, 1997. View at Scopus
  81. S. Ananthnarayan, J. Bahng, J. Roring et al., “Time course of imaging changes of GBM during extended bevacizumab treatment,” Journal of Neuro-Oncology, vol. 88, no. 3, pp. 339–347, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. A. D. Norden, G. S. Young, K. Setayesh et al., “Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence,” Neurology, vol. 70, no. 10, pp. 779–787, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Y. Wen, D. R. Macdonald, D. A. Reardon et al., “Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group,” Journal of Clinical Oncology, vol. 28, no. 11, pp. 1963–1972, 2010. View at Publisher · View at Google Scholar · View at Scopus
  84. E. M. Haacke, Y. Xu, Y. C. N. Cheng, and J. R. Reichenbach, “Susceptibility weighted imaging (SWI),” Magnetic Resonance in Medicine, vol. 52, no. 3, pp. 612–618, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Rauscher, J. Sedlacik, M. Barth, H. J. Mentzel, and J. R. Reichenbach, “Magnetic susceptibility-weighted MR phase imaging of the human brain,” American Journal of Neuroradiology, vol. 26, no. 4, pp. 736–742, 2005. View at Scopus
  86. S. M. Park, H. S. Kim, G. H. Jahng, C. W. Ryu, and S. Y. Kim, “Combination of high-resolution susceptibility-weighted imaging and the apparent diffusion coefficient: added value to brain tumour imaging and clinical feasibility of non-contrast MRI at 3 T,” British Journal of Radiology, vol. 83, no. 990, pp. 466–475, 2010. View at Publisher · View at Google Scholar · View at Scopus
  87. G. A. Christoforidis, M. Yang, A. Abduljalil et al., ““Tumoral pseudoblush” identified within gliomas at high-spatial-resolution ultrahigh-field-strength gradient-echo MR imaging corresponds to microvascularity at stereotactic biopsy,” Radiology, vol. 264, no. 1, pp. 210–217, 2012.
  88. G. Grabner, I. Nobauer, K. Elandt et al., “Longitudinal brain imaging of five malignant glioma patients treated with bevacizumab using susceptibility-weighted magnetic resonance imaging at 7 T,” Magnetic Resonance Imaging, vol. 30, no. 1, pp. 139–147, 2012.
  89. M. E. De Backer, R. J. A. Nabuurs, M. A. Van Buchem, and L. Van Der Weerd, “MR-based molecular imaging of the brain: the next frontier,” American Journal of Neuroradiology, vol. 31, no. 9, pp. 1577–1583, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. B. Tomanek, U. Iqbal, B. Blasiak et al., “Evaluation of brain tumor vessels specific contrast agents for glioblastoma imaging,” Neuro-Oncology, vol. 14, no. 1, pp. 53–63, 2012.
  91. T. He, N. Smith, D. Saunders et al., “Molecular MRI assessment of vascular endothelial growth factor receptor-2 in rat C6 gliomas,” Journal of Cellular and Molecular Medicine, vol. 15, no. 4, pp. 837–849, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. K. Herholz, W. Heindel, P. R. Luyten et al., “In vivo imaging of glucose consumption and lactate concentration in human gliomas,” Annals of Neurology, vol. 31, no. 3, pp. 319–327, 1992. View at Scopus
  93. J. R. Alger, J. A. Frank, A. Bizzi et al., “Metabolism of human gliomas: assessment with H-1 MR spectroscopy and F-18 fluorodeoxyglucose PET,” Radiology, vol. 177, no. 3, pp. 633–641, 1990. View at Scopus
  94. C. Rémy, N. Fouilhé, I. Barba et al., “Evidence that mobile lipids detected in rat brain glioma by 1H nuclear magnetic resonance correspond to lipid droplets,” Cancer Research, vol. 57, no. 3, pp. 407–414, 1997. View at Scopus
  95. P. Zonari, P. Baraldi, and G. Crisi, “Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planar perfusion imaging,” Neuroradiology, vol. 49, no. 10, pp. 795–803, 2007. View at Publisher · View at Google Scholar · View at Scopus
  96. M. E. Meyerand, J. M. Pipas, A. Mamourian, T. D. Tosteson, and J. F. Dunn, “Classification of biopsy-confirmed brain tumors using single-voxel MR spectroscopy,” American Journal of Neuroradiology, vol. 20, no. 1, pp. 117–123, 1999. View at Scopus
  97. D. Yang, Y. Korogi, T. Sugahara et al., “Cerebral gliomas: prospective comparison of multivoxel 2D chemical-shift imaging proton MR spectroscopy, echoplanar perfusion and diffusion-weighted MRI,” Neuroradiology, vol. 44, no. 8, pp. 656–666, 2002. View at Publisher · View at Google Scholar · View at Scopus
  98. X. Li, D. B. Vigneron, S. Cha et al., “Relationship of MR-derived lactate, mobile lipids, and relative blood volume for gliomas in vivo,” American Journal of Neuroradiology, vol. 26, no. 4, pp. 760–769, 2005. View at Scopus
  99. A. J. Kumar, N. E. Leeds, G. N. Fuller et al., “Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment,” Radiology, vol. 217, no. 2, pp. 377–384, 2000. View at Scopus
  100. M. E. Mullins, G. D. Barest, P. W. Schaefer, F. H. Hochberg, R. G. Gonzalez, and M. H. Lev, “Radiation necrosis versus glioma recurrence: conventional MR imaging clues to diagnosis,” American Journal of Neuroradiology, vol. 26, no. 8, pp. 1967–1972, 2005. View at Scopus
  101. T. Nakajima, T. Kumabe, M. Kanamori et al., “Differential diagnosis between radiation necrosis and glioma progression using sequential proton magnetic resonance spectroscopy and methionine positron emission tomography,” Neurologia Medico-Chirurgica, vol. 49, no. 9, pp. 394–401, 2009. View at Publisher · View at Google Scholar · View at Scopus
  102. R. F. Barajas Jr., J. S. Chang, M. R. Segal et al., “Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging,” Radiology, vol. 253, no. 2, pp. 486–496, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. V. A. Larsen, H. J. Simonsen, I. Law, H. B. Larsson, and A. E. Hansen, “Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis,” Neuroradiology, vol. 55, no. 3, pp. 361–369, 2013.
  104. B. Hakyemez, C. Erdogan, N. Yildirim, and M. Parlak, “Glioblastoma multiforme with atypical diffusion-weighted MR findings,” British Journal of Radiology, vol. 78, no. 935, pp. 989–992, 2005. View at Publisher · View at Google Scholar · View at Scopus
  105. A. Batra and R. P. Tripathi, “Atypical diffusion-weighted magnetic resonance findings in glioblastoma multiforme,” Australasian Radiology, vol. 48, no. 3, pp. 388–391, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. I. C. Chiang, T. J. Hsieh, M. L. Chiu, G. C. Liu, Y. T. Kuo, and W. C. Lin, “Distinction between pyogenic brain abscess and necrotic brain tumour using 3-tesla MR spectroscopy, diffusion and perfusion imaging,” British Journal of Radiology, vol. 82, no. 982, pp. 813–820, 2009. View at Publisher · View at Google Scholar · View at Scopus
  107. C. H. Toh, K. C. Wei, C. N. Chang et al., “Differentiation of pyogenic brain abscesses from necrotic glioblastomas with use of susceptibility-weighted imaging,” American Journal of Neuroradiology, vol. 33, no. 8, pp. 1534–1538, 2012.